Ifp Advisors, Inc Exact Sciences Corp Transaction History

Ifp Advisors, Inc

$2.42 Billion
Q2 2024

A detailed history of Ifp Advisors, Inc transactions in Exact Sciences Corp stock. As of the latest transaction made, Ifp Advisors, Inc holds 225 shares of EXAS stock, worth $13,522. This represents 0.0% of its overall portfolio holdings.

Number of Shares

225

Previous 155 45.16%

Holding current value

$13,522

Previous $10,000 10.0%

% of portfolio

0.0%

Previous 0.0%

35 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 30, 2024	BUY	$41.33 - $74.26 $2,893 - $5,198	70 Added 45.16%	225 $9,000
Q1 2024 Jul 30, 2024	BUY	$56.27 - $73.77 $112 - $147	2 Added 1.31%	155 $10,000
Q4 2023 Jan 09, 2024	SELL	$59.06 - $75.72 $5,492 - $7,041	-93 Reduced 37.8%	153 $11,000
Q3 2023 Oct 12, 2023	BUY	$65.94 - $99.04 $5,604 - $8,418	85 Added 52.8%	246 $16,000
Q2 2023 Aug 04, 2023	SELL	$62.68 - $95.05 $26,889 - $40,776	-429 Reduced 72.71%	161 $15,000
Q1 2023 Apr 18, 2023	SELL	$47.19 - $70.77 $165,259 - $247,836	-3,502 Reduced 85.58%	590 $40,000
Q4 2022 Feb 07, 2023	BUY	$30.35 - $53.15 $18,331 - $32,102	604 Added 17.32%	4,092 $250,000
Q3 2022 Nov 08, 2022	BUY	$31.97 - $49.37 $42,072 - $64,970	1,316 Added 60.59%	3,488 $218,000
Q2 2022 Sep 06, 2022	BUY	$35.61 - $76.23 $77,344 - $165,571	2,172 New	2,172 $139,000
Q2 2022 Aug 12, 2022	SELL	$35.61 - $76.23 $77,344 - $165,571	-2,172 Closed	0 $0
Q1 2022 Sep 06, 2022	BUY	$57.56 - $82.54 $68,438 - $98,140	1,189 Added 120.96%	2,172 $151,000
Q1 2022 Aug 08, 2022	BUY	$57.56 - $82.54 $2,302 - $3,301	40 Added 4.24%	983 $68,000
Q4 2021 Jan 12, 2022	SELL	$72.5 - $100.68 $76,052 - $105,613	-1,049 Reduced 52.66%	943 $74,000
Q3 2021 Oct 06, 2021	BUY	$90.24 - $124.05 $26,981 - $37,090	299 Added 17.66%	1,992 $189,000
Q2 2021 Jul 13, 2021	BUY	$93.66 - $139.27 $22,291 - $33,146	238 Added 16.36%	1,693 $208,000
Q1 2021 Apr 30, 2021	BUY	$116.57 - $155.01 $52,573 - $69,909	451 Added 44.92%	1,455 $194,000
Q4 2020 Jan 25, 2021	BUY	$99.61 - $142.12 $2,091 - $2,984	21 Added 2.14%	1,004 $135,000
Q3 2020 Oct 29, 2020	SELL	$72.92 - $102.01 $6,198 - $8,670	-85 Reduced 7.96%	983 $102,000
Q2 2020 Aug 05, 2020	BUY	$55.75 - $92.75 $31,777 - $52,867	570 Added 114.46%	1,068 $90,000
Q1 2020 May 12, 2020	SELL	$37.9 - $104.44 $11,711 - $32,271	-309 Reduced 38.29%	498 $31,000
Q4 2019 Jan 17, 2020	SELL	$77.66 - $99.74 $280,973 - $360,859	-3,618 Reduced 81.76%	807 $77,000
Q3 2019 Nov 07, 2019	BUY	$90.37 - $122.49 $192,578 - $261,026	2,131 Added 92.89%	4,425 $405,000
Q1 2019 May 15, 2019	SELL	$61.98 - $96.5 $268,187 - $417,555	-4,327 Reduced 65.35%	2,294 $202,000
Q4 2018 Jan 23, 2019	BUY	$56.04 - $82.66 $24,041 - $35,461	429 Added 6.93%	6,621 $417,000
Q3 2018 Oct 25, 2018	BUY	$48.29 - $80.6 $98,849 - $164,988	2,047 Added 49.38%	6,192 $0
Q2 2018 Aug 07, 2018	SELL	$37.84 - $69.96 $521,775 - $964,678	-13,789 Reduced 76.89%	4,145 $0
Q1 2018 Jun 03, 2019	BUY	$39.82 - $57.53 $429,697 - $620,806	10,791 Added 151.07%	17,934 $942,000
Q1 2018 May 09, 2018	SELL	$39.82 - $57.53 $429,697 - $620,806	-10,791 Reduced 60.17%	7,143 $0
Q4 2017 Jan 24, 2018	SELL	$46.49 - $60.51 $444,397 - $578,415	-9,559 Reduced 34.77%	17,934 $0
Q3 2017 Oct 30, 2017	BUY	$37.05 - $47.12 $505,473 - $642,858	13,643 Added 98.51%	27,493 $1.3 Million
Q2 2017 Jun 03, 2019	BUY	N/A	10,517 Added 315.54%	13,850 $490,000
Q1 2017 Jun 03, 2019	BUY	N/A	2,940 Added 748.09%	3,333 $79,000
Q4 2016 Jun 03, 2019	SELL	N/A	-12,526 Reduced 96.96%	393 $5,000
Q2 2016 Jun 03, 2019	BUY	N/A	10,625 Added 463.16%	12,919 $158,000
Q1 2016 Jun 03, 2019	BUY	N/A	2,294	2,294 $202,000

Others Institutions Holding EXAS

# of Institutions

672

Shares Held

163M

Call Options Held

2.58M

Put Options Held

2.19M

View Full List

About EXACT SCIENCES CORP

Ticker EXAS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 176,960,000
Market Cap $10.6B
Description
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...

More about EXAS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ifp Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ifp Advisors, Inc with notifications on news.

Account